

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Status: Recruiting

Eligibility Criteria

Age: 12 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

- Male or female subjects, ≥12 years of age (≥ 18 years of age for subjects at German sites only), undergoing HCT for hematological malignancies, including leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome and myeloproliferative neoplasms
- Planned myeloablative conditioning regimen

Exclusion Criteria:

- Prior autologous or allogeneic HCT
- T-cell depleted transplant or planned use of anti-T cell antibody therapy either ex vivo or in vivo (ie, anti-thymocyte globulin [ATG], alemtuzumab) for GVHD prophylaxis
- Planned umbilical cord blood (UCB) transplant

Conditions & Interventions

Interventions:

Biological: Alpha-1 antitrypsin (AAT), Biological: Placebo

Conditions:

Acute-graft-versus-host Disease

More Information

Contact(s): Trial Registration Coordinator - clinicaltrials@csllabehring.com

Principal Investigator:

Phase: Phase 2/Phase 3

IRB

Number:

System ID: NCT03805789

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact ctrrecruit@vcu.edu if you have questions or need assistance.